4//SEC Filing
Becker Daniel J. 4
Accession 0000899243-20-031744
CIK 0001807901other
Filed
Nov 18, 7:00 PM ET
Accepted
Nov 19, 8:15 PM ET
Size
10.6 KB
Accession
0000899243-20-031744
Insider Transaction Report
Form 4
Becker Daniel J.
Director
Transactions
- Purchase
Common Stock
2020-11-17$14.63/sh+2,170$31,747→ 2,602,943 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$15.43/sh+13,027$201,007→ 2,615,970 total(indirect: See footnote) - Purchase
Common Stock
2020-11-18$15.26/sh+14,197$216,646→ 2,630,167 total(indirect: See footnote)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.20 per share to $15.00 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The shares reported are held directly by AI Pan LLC ("AI Pan"). Each of Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik may be deemed to beneficially own the Issuer's shares beneficially owned by AI Pan, a subsidiary in a multi-tier corporate structure of which Access Industries Holdings LLC is the parent holding company and is ultimately managed by Access Industries Management, LLC and controlled by Mr. Blavatnik. Mr. Becker is a biotechnology principal of Access Industries, Inc., an affiliate of Access Industries Management LLC, and does not have voting or dispositive power over the shares held by AI Pan. Mr. Becker disclaims beneficial ownership of the shares held by AI Pan.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.20 per share to $15.50 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.10 per share to $15.50 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Documents
Issuer
Pandion Therapeutics, Inc.
CIK 0001807901
Entity typeother
Related Parties
1- filerCIK 0001752139
Filing Metadata
- Form type
- 4
- Filed
- Nov 18, 7:00 PM ET
- Accepted
- Nov 19, 8:15 PM ET
- Size
- 10.6 KB